| Literature DB >> 35124895 |
Yoonhyuk Jang1, Seondeuk Kim1, Won-Sang Cho2, Jangsup Moon1,3, Kon Chu1, Narae Kim1, Hyoshin Son2, Eun Jin Ha2, Eun Jung Koh2,4, Ji Hoon Phi2,4, Chul-Kee Park2, Jeong Eun Kim2, Seung-Ki Kim2,4, Sang Kun Lee1.
Abstract
OBJECTIVE: Nosocomial bacterial meningitis is one of the major complications after neurosurgery. We performed nanopore 16S amplicon sequencing from cerebrospinal fluid (CSF) to evaluate bacterial meningitis in patients who underwent neurosurgery.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35124895 PMCID: PMC8935320 DOI: 10.1002/acn3.51517
Source DB: PubMed Journal: Ann Clin Transl Neurol ISSN: 2328-9503 Impact factor: 4.511
Figure 1Study cohort profiles. Two hundred eighty‐five samples for nanopore 16S amplicon sequencing were obtained from 178 patients who underwent neurosurgery. Among them, 40 samples were sequencing positive, and 23 samples were culture positive. While all 40 sequencing‐positive samples were genuine infection, 18 culture‐positive samples were identified as genuine infection, and five were suspected of being contaminated. The final number of samples that were genuine infection was 41. Among the 40 sequencing‐positive samples, only 17 samples showed consistent results with the culture study, and 23 samples showed false‐negative results of the culture study. These were also divided into groups of initial samples (n = 30) and follow‐up samples (n = 10) depending on when the samples were collected. In each group, the numbers of false‐negative results of the culture study were 15 and 8, respectively. [Colour figure can be viewed at wileyonlinelibrary.com]
Characteristics of samples from neurosurgery and association with risk factors.
| Total | None ( | Genuine Infection ( |
| Univariable analysis | Multivariable analysis | ||
| OR (95% CI) |
| OR (95% CI) |
| ||||
| Patients |
|
| |||||
| Age (yrs) | 49.9 ± 21.7 | 50.4 ± 23.8 | 0.756 | 1.002 (0.989–1.016) | 0.741 | 1.002 (0.985–1.019) | 0.819 |
| Sex (Male) | 81 (52.9%) | 17 (63.0%) | 0.230 | 1.60 (0.805–3.331) | 0.191 | 0.845 (0.334–2.133) | 0.720 |
| Risk factors | |||||||
| CNS Foreign Body | 52 (21.3%) | 17 (41.5%) | 0.009 | 2.615 (1.294–5.211) | 0.00653 | 3.311 (1.509–7.246) | 0.003 |
| Alcoholics | 25 (10.3%) | 10 (24.4%) | 0.018 | 2.826 (1.197–6.316) | 0.0135 | 3.422 (1.191–9.868) | 0.022 |
| Systemic cancer | 15 (6.1%) | 5 (12.2%) | 0.182 | 2.120 (0.657–5.857) | 0.169 | ||
| HTN | 88 (36.1%) | 16 (39.0%) | 0.728 | 1.135 (0.566–2.222) | 0.716 | ||
| DM | 32 (13.1%) | 6 (14.6%) | 0.804 | 1.136 (0.405–2.749) | 0.791 | ||
| Insulin | 5 (2.1%) | 0 | 1 | NA | |||
| Craniotomy | 87 (35.6%) | 11 (26.8%) | 0.293 | 0.662 (0.3040–1.350) | 0.273 | ||
| Diagnosis | |||||||
| Brain tumor | 80 (32.8%) | 12 (29.3%) | 0.721 | 0.848 (0.398–1.713) | 0.656 | ||
| EDH | 6 (2.5%) | 1 (2.4%) | 1 | 0.992 (0.052–6.018) | 0.994 | ||
| SDH | 25 (10.3%) | 3 (7.3%) | 0.778 | 0.692 (0.159–2.099) | 0.562 | ||
| SAH | 73 (29.9%) | 12 (29.3%) | 1 | 0.969 (0.454–1.963) | 0.933 | ||
| IPH | 57 (23.4%) | 8 (19.5%) | 0.690 | 0.795 (0.326–1.743) | 0.587 | ||
| IVH | 70 (28.7%) | 8 (19.5%) | 0.260 | 0.603 (0.249–1.310) | 0.226 | ||
| Vascular occlusion | 4 (1.6%) | 1 (2.4%) | 0.543 | 1.500 (0.076–10.463) | 0.72 | ||
| Aneurysm | 4 (1.6%) | 0 | 1 | NA | |||
| Congenital defect | 6 (2.5%) | 2 (4.9%) | 0.323 | 2.034 (0.291–9.198) | 0.395 | ||
| Hydrocephalus | 17 (7.0%) | 6 (14.6%) | 0.117 | 2.289 (0.783–5.936) | 0.103 | ||
| Shunt malfunction | 41 (16.8%) | 15 (36.6%) | 0.005 | 2.856 (1.370–5.818) | 0.0042 | ||
| Hemifacial spasm | 3 (1.2%) | 0 | 1 | NA | |||
| Other diagnosis | 2 (0.8%) | 0 | 1 | NA | |||
| Symptom or sign | |||||||
| postOP fever | 175 (71.7%) | 36 (87.8%) | 0.033 | 2.839 (1.163–8.524) | 0.0361 | 4.880 (1.815–16.091) | 0.004 |
| CSF leakage | 14 (5.7%) | 4 (9.8%) | 0.305 | 1.776 (0.483–5.269) | 0.334 | ||
| Wound problem | 25 (10.3%) | 2 (4.9%) | 0.392 | 0.449 (0.071–1.593) | 0.289 | ||
| Neurologic change | 21 (8.6%) | 8 (19.5%) | 0.047 | 2.574 (1.003–6.106) | 0.0379 | 2.618 (0.904–7.241) | 0.067 |
| Other reasons | 24 (9.8%) | 3 (7.3%) | 0.778 | 0.724 (0.166–2.204) | 0.612 | ||
CI, confidence interval, yrs., years, CNS, central nervous system, HTN, hypertension, DM, diabetes mellitus, EDH, epidural hemorrhage, SDH, subdural hemorrhage, SAH, subarachnoid hemorrhage, IPH, intraparenchymal hemorrhage, IVH, intraventricular hemorrhage, postOP, postoperative
p < 0.05.
Analysis of initial samples with nanopore 16S sequencing positive and the culture test false‐negative rate.
| Total | Culture negative ( | Culture positive ( |
Culture test false‐negative rate |
|
|---|---|---|---|---|
| Patients |
|
| ||
| Age (yrs) | 47.5 (sd 7.4) | 49.6 (sd 6.4) | 0.833 | |
| Sex (Male) | 10 (66.7%) | 10 (66.7%) | 1 | |
| Risk factors | ||||
| CNS Foreign Body | 3 (20%) | 9 (60%) | 25% | 0.06 |
| Alcoholics | 4 (26.7%) | 4 (26.7%) | 50% | 1 |
| Systemic cancer | 3 (20%) | 0 | 100% | 0.224 |
| HTN | 7 (46.7%) | 5 (33. 3%) | 58.3% | 0.71 |
| DM | 3 (20%) | 2 (13.3%) | 60% | 1 |
| Insulin | 0 | 0 | NA | NA |
| Craniotomy | 4 (26.7%) | 5 (33.3%) | 44.4% | 1 |
| Diagnosis | ||||
| Brain tumor | 5 (33.3%) | 4 (26.7%) | 55.6% | 1 |
| EDH | 0 | 0 | NA | |
| SDH | 1 (6.7%) | 1 (6.7%) | 50% | 1 |
| IPH | 4 (26.7%%) | 2 (13.3%) | 66.7% | 0.651 |
| SAH | 7 (46.7%) | 2 (13.3%) | 77.8% | 0.109 |
| IVH | 7 (46.7%) | 0 | 100% | 0.006 |
| Vascular occlusion | 0 | 1 (6.7%) | 0 | 1 |
| Aneurysm | 0 | 0 | NA | NA |
| Congenital defect | 0 | 1 (6.7%) | 0 | 1 |
| Hydrocephalus | 3 (20%) | 2 (13.3%) | 60% | 1 |
| Shunt malfunction | 3 (20%) | 8 (53.3%) | 27.3% | 0.128 |
| Hemifacial spasm | 0 | 0 | NA | NA |
| Other diagnosis | 0 | 0 | NA | NA |
| Symptom or sign | ||||
| postOP fever | 12 (80%) | 13 (86.7%) | 48% | 1 |
| CSF leakage | 1 (6.7%) | 3 (20%) | 25% | 0.598 |
| Wound problem | 0 | 2 (13.3%) | 0 | 0.483 |
| Neurologic change | 4 (26.7%) | 1 (6.7%) | 80% | 0.33 |
| Other reasons | 1 (6.7%) | 1 (6.7%) | 50% | 1 |
yrs, years, sd, standard deviation, CNS, central nervous system, HTN, hypertension, DM, diabetes mellitus, EDH, epidural hemorrhage, SDH, subdural hemorrhage, IPH, intraparenchymal hemorrhage, SAH, subarachnoid hemorrhage, IVH, intraventricular hemorrhage, postOP, postoperative.
p < 0.05.
Detailed profile of patients who had mismatch results between microbial culture and nanopore 16S sequencing.
| Patient ID | Sex/age | Diagnosis | Operation | Risk factors | Reason for nanopore sequencing | Day (OP to CSF study) | CSF profiles | Systemic infection | Blood or other system culture result | CSF culture result | 16S sequencing Result | ABX | Change of actions, based on 16S Seq |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group A: CNS infection accompanied by Systemic infection, confirmed by nanopore 16S sequencing | |||||||||||||
| A#1 | M/75 | Ventriculitis with IVH | EVD | Pancreatic head cancer | Progression of Hydrocephalus with neurologic change | 0 |
R81 W900(P90 L7 O3), Ptn665 Glc23 Glc ratio 0.15 | Sepsis, UTI, Liver abscess |
| Negative |
|
Vancomycin, Ceftazidime, Metronidazole ➔ Ceftriaxone | ABX narrow down |
| A#2 | F/80 | SAH, ICH | Coil embolization of cerebral aneurysm | Alcoholics, HTN, DM, Lumbar catheter | Postop fever | 7 |
R1725 W1170(P91 L6 O3), Ptn212, Glc49 Glc ratio0.26 | Sepsis, UTI |
ESBL (+) (Meropenem I): Blood/Urine/Tip | Negative |
|
Meropenem, Gentamycin ➔ IV/IT Colistin | ABX escalation |
| A#3 | M/51 | SAH, IVH | EVD | Alcoholics, HTN, DM | Postop fever | 20 |
R1 W3960(P90 L1 O9), Ptn343, Glc64 Glc ratio 0.32 | Sepsis (CRBSI) |
(Cefepime S): Blood/Tip | Negative |
|
Vancomycin, Cefepime ➔ Linezolid | ABX escalation |
| A#4 | M/56 | Metastatic cancer to the brain | Craniotomy and tumor removal | Left frontal sinus cancer | Postop fever | 9 |
R12 W11(P18 L64 O18) Ptn74 Glc 74 Glc ratio NA | Pneumonia |
(Ceftriaxone S): Sputum only | Negative |
|
Vancomycin, Ceftazidime ➔ Metronidazole, Ceftriaxone | ABX change |
| A#5 | M/63 | ICH, IVH | EVD | Alcoholics, Rectal cancer | Postop fever | 14 |
R870 W580(P53 L12 O35), Ptn82 Glc110 Glc ratio NA | Cellulitis |
(Oxacillin R): Skin only | Negative |
| Vancomycin, Ceftazidime | ABX maintenance |
| A#6 | M/60 | Tuberculum sellae meningioma | Endoscopic extended skull base TSA and tumor removal | Alcoholics, HTN | Postop CSF leak | 12 |
R NA W18600(P87 L0 O13) Ptn574 Glc1 Glc ratio < 0.01 | Sepsis |
(Ceftriaxone R, Vancomycin S): Blood | Negative |
| Vancomycin, Ceftazidime | Abx maintenance |
| Group B: isolated CNS infection, confirmed by nanopore 16S sequencing | |||||||||||||
| B#1 | M/7 | Cerebellar pilocytic astrocytoma | Craniotomy and tumor removal | None | Postop fever | 12 |
R403 W5584(P81 L4 O15) Ptn143 Glc59 Glc ratio NA | None | Negative | Negative |
|
Vancomycin, Ceftazidime ➔ Vancomycin | ABX narrow down |
| B#2 | M/1 | Germ cell tumor, immature teratoma, intracranial | Shunt revision | VP shunt | Postop fever | 3 |
R432 W5490(P88 L2 O10) Ptn600 Glc < 5 Glc ratio NA | None | Negative | Negative |
|
Vancomycin, Ceftazidime ➔ Vancomycin, Cefepime | ABX escalation, VPS removal |
| B#3 | F/71 | SAH | Craniotomy and cerebral aneurysm clipping | HTN | Postop fever | 5 |
R80000 W900(P91 L5 O4), Ptn268 Glc40 Glc ratio 0.39 | None | Negative | Negative |
| Vancomycin, Ceftazidime | ABX maintenance, Wound revision & bone flap removal |
| B#4 | M/15 | Diffuse midline glioma | VP shunt | VP shunt | Neurologic change (mental change) | 23 |
R390 W20(P10 L20 O70) Ptn148 Glc91 Glc ratio NA | None |
| Negative |
| Vancomycin, Meropenem | ABX maintenance |
| B#5 | F/32 | SAH, IVH | EVD | None | Postop fever | 4 |
R92000 W1386(P89 L8 O3), Ptn500 Glc2 Glc ratio NA | None | Negative | Negative |
| Vancomycin, Ceftazidime | ABX maintenance |
| B#6 | F/69 | SAH, IVH | EVD | HTN, DM | CSF abnormality | 3 |
R174000 W2598(P77 L5 O18) Ptn 132 Glc 103 Glc ratio 33.0 | None | Negative | Negative |
| None | None |
| Group C: follow‐up sample mismatch result, confirmed by nanopore 16S sequencing | |||||||||||||
| C#1 | F/63 | Metastatic cancer to the brain | Ommaya insertion | Breast cancer, Ommaya | Postop fever | 7 |
R77 W135(P29 L22 O49) Ptn 38 Glc 59 Glc ratio NA | None | Negative |
Unidentified Gram (+) rod (Vancomycin S) ➔ Negative (FU) |
|
Vancomycin, Ceftazidime ➔ Vancomycin | ABX narrow down & maintenance |
| C#2 | M/38 | Ventriculitis | EVD | None | Postop fever Altered mentality | 3 |
R477 W234(P68 L28 O4) Ptn 334 Glu 22 Glc ratio NA | None | Negative |
➔ Negative (FU) |
|
Vancomycin, Ceftazidime ➔ Ceftazidime |
ABX narrow down & maintenance |
| C#3 | M/3 | Hydrocephalus | VP shunt | VP shunt | Fever | 1210 |
R54 W4(P100 L0 O0) Ptn24 Glc58 Glc ratio NA | None | Negative |
(Oxacillin R) ➔ Negative (FU) |
| Vancomycin, Rifampin | ABX maintenance, VPS removal |
| C#4 | M/6 | Holoprosencephaly | VP shunt | VP shunt | Fever | 167 |
R100 W10(P20 L4‐ O40) Ptn 124 Glc 43 Glc ratio NA | None | Negative |
➔ Negative (FU) |
|
Vancomycin, cefotaxime ➔ Vancomycin, Rifampin | ABX maintenance |
| C#5 | F/79 | SAH, ICH, IVH | Cranioplasty with autologous bone | HTN | Fever | 8 |
R27700 W160(P18 L51 O31) Ptn 116 Glc 128 Glc ratio NA | None | Negative |
➔ Negative (FU) |
|
Vancomycin, Meropenem ➔ Vancomycin | ABX maintenance |
ID, identification, OP, operation, CSF, cerebrospinal fluid, ABX, antibiotics, Seq, sequence, CNS, central nervous system, M, male, F, female, IVH, intraventricular hemorrhage, EVD, extraventricular drainage, R, red blood cell, W, white blood cell, P, polymorphonuclear leukocytes, L, lymphocyte, O, others, Ptn, protein, Glc, glucose, Glc ratio, CSF glucose/serum glucose ratio, UTI, urinary tract infection, S, susceptible, I, intermediate, R, resistant, PCD, percutaneous drainage, SAH, subarachnoid hemorrhage, ICH, intracerebral hemorrhage, HTN, hypertension, DM, diabetes mellitus, Postop, postoperative, ESBL, extended‐spectrum β‐lactamase, IV, intravenous, IT, intrathecal, CRBSI, central‐related bloodstream infection, TSA, transsphenoidal approach, VP, ventriculoperitoneal, VPS, ventriculoperitoneal shunt, FU, follow‐up.
Figure 2Representative Cases of 16S Sequencing Culture Mismatching. (A) A representative case of Group A. A 75‐year‐old man developed fever, and a systemic study revealed liver abscess (A‐1), complicated urinary tract infection, and sepsis. He showed altered mentality, and brain computed tomography (CT) revealed signs of ventriculitis (day 3) (A‐2). Thus, extraventricular drainage (EVD) was inserted (day 5). While the systemic culture study isolated 2nd generation cephalosporin susceptible Klebsiella pneumoniae, a negative result was shown in the culture study of cerebrospinal fluid (CSF) obtained from EVD. However, nanopore 16S amplicon sequencing detected K. pneumoniae (red‐filled triangle), which was a consistent result with that of the systemic culture study (day 9). Based on the susceptibility results of the systemic culture study, the empirical antibiotics were narrowed down to ceftriaxone monotherapy. (B) A representative case of Group B. A 71‐year‐old female had severe headache and was diagnosed with subarachnoid hemorrhage (SAH) due to aneurysmal rupture (B‐1). She underwent craniotomy and cerebral aneurysm clipping surgery. Postoperative fever occurred after 5 days (day 0). All conventional culture studies showed negative results, but only nanopore 16S amplicon sequencing of CSF detected Staphylococcus caprae (day 1). Brain CT supported the possibility of surgical site infection (B‐2). Therefore, wound revision and bone flap removal surgery were performed (day 6). (C) A representative case of Group C. A 3‐year‐old boy with a history of congenital hydrocephalus was diagnosed with ventriculoperitoneal (VP) shunt infection. An initial (day 0, not shown) and the first follow‐up (day 18) culture study of CSF samples isolated Staphylococcus aureus. While the additional follow‐up culture study showed a negative result, nanopore 16S amplicon sequencing detected S. aureus (day 27). The clinicians decided to remove the VP shunt (day 33), and the culture study with the removed shunt revealed S. aureus, the consistent pathogen with 16S amplicon sequencing. Therefore, antibiotic treatment was maintained until the final follow‐up study result (day 35), which was negative. PCD, percutaneous catheter drainage; IntraOP, intraoperation; CSF, cerebrospinal fluid; FU, follow‐up; FB, foreign body. [Colour figure can be viewed at wileyonlinelibrary.com]